Lancashire and South Cumbria
Formulary
9 Nutrition and blood
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents:
mlcsu.lscformulary@nhs.net
.
For more information about the formulary development process, please see:
https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
09-01-03 Iron overload
Links
LSCMMG: Bariatric surgery guidelines for prescribing of vitamins and nutritional supplements: Position Statement
LSCMMG: Gluten-Free food products: Position Statement
LSCMMG: Oral Nutritional Supplements in Primary Care
LSCMMG: PKU - Prescribing of Multivitamins & Phenylalanine-free amino acid substitutes for adults and children
LSCMMG: Rituximab Intravenous Infusion for the Treatment of Autoimmune Haemolytic Anaemia (AIHA) in Adults NMR
LSCMMG: Rituximab Intravenous Infusion For treatment of Idiopathic Thrombocytopenia Purpura (ITP) in adults NMR
MHRA: Recombinant human erythropoietins: new advice for prescribing
MHRA: Recombinant human erythropoietins: new advice for prescribing
MHRA: Recombinant human erythropoietins: treating anaemia in cancer
MHRA: Recombinant human erythropoietins: treating anaemia in cancer
MHRA: Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)
MHRA: Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)
MHRA: Rituximab: screen for hepatitis B virus before treatment
NHSE: Clinical Commissioning Policy Treatment of iron overload for transfused and non-transfused patients with chronic inherited anaemias (all ages) (URN 2109) [221004P]
NHSE: Clinical Commissioning Policy: Treatment of iron overload for transfused and non transfused patients with chronic inherited anaemias
NICE CG32: Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition
NICE NG20: Coeliac disease: recognition, assessment and management
NICE NG203: Chronic kidney disease: assessment and management
NICE TA1000: Iptacopan for treating paroxysmal nocturnal haemoglobinuria
NICE TA1010: Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria
NICE TA1019: Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over
NICE TA1035: Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease
NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
NICE TA636: Eculizumab for treating refractory myasthenia gravis (terminated appraisal)
NICE TA647: Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)
NICE TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria
NICE TA698:Ravulizumab for treating paroxysmal nocturnal haemoglobinuria
NICE TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
NICE TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
NICE TA743: Crizanlizumab for preventing sickle cell crises in sickle cell disease
NICE TA981: Voxelotor for treating haemolytic anaemia caused by sickle cell disease
Key
Full Site